dalteparin has been researched along with Hypertension in 18 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of | 5.14 | The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009) |
| "A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%." | 3.96 | Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. ( Bartoletti, M; Viale, P, 2020) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| " Recently, the use of safe-dose recombinant tissue-type plasminogen activator (rTPA) has been proposed for the treatment of moderate PE demonstrating to be safe and more effective than standard anticoagulation." | 2.50 | [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature]. ( Cannone, M; La Torre, PP; Mele, A; Mele, M, 2014) |
| "Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously." | 1.56 | Potential drug-drug interactions in ICU patients: a retrospective study. ( Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020) |
| "Preeclampsia is a serious hypertensive disorder of pregnancy, which is only cured with delivery of the placenta, thereby commonly necessitating preterm birth of the fetus." | 1.56 | The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†. ( Baczyk, D; Kingdom, JC; Wat, JM, 2020) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | 1.39 | Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Okmen, E | 1 |
| Ozen, E | 1 |
| Uyarel, H | 1 |
| Sanli, A | 1 |
| Tartan, Z | 1 |
| Cam, N | 1 |
| Wanic-Kossowska, M | 1 |
| Kozioł, L | 1 |
| Roszkowiak, B | 1 |
| Lacka, M | 1 |
| Frankiewicz, D | 1 |
| Mandel, M | 1 |
| Calderero Aragón, V | 1 |
| de Gregorio Ariza, MA | 1 |
| Pazo Cid, R | 1 |
| Puértolas Hernández, T | 1 |
| Lostalé Latorre, F | 1 |
| Artal Cortés, A | 1 |
| Antón Torres, A | 1 |
| Gersch, K | 1 |
| Spencer, TR | 1 |
| Viale, P | 1 |
| Bartoletti, M | 1 |
| Ali, I | 1 |
| Bazzar, A | 1 |
| Hussein, N | 1 |
| Sahhar, E | 1 |
| Mele, M | 1 |
| Mele, A | 1 |
| La Torre, PP | 1 |
| Cannone, M | 1 |
| Listernick, R | 1 |
| Yildiz, M | 1 |
| Karakoyun, S | 1 |
| Acar, RD | 1 |
| Ozkan, M | 1 |
| Miguélez, A | 1 |
| Barrientos, N | 1 |
| López-Ríos, F | 1 |
| Vanaclocha, F | 1 |
| Iglesias, L | 1 |
| Chazova, IE | 1 |
| Mychka, VB | 1 |
| Mamyrbaeva, KM | 1 |
| Gornostaev, VV | 1 |
| Dvoskina, IM | 1 |
| Sergienko, VB | 1 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Wat, JM | 1 |
| Baczyk, D | 1 |
| Kingdom, JC | 1 |
| Sare, GM | 1 |
| Bath, PM | 3 |
| Gray, LJ | 2 |
| Moulin, T | 2 |
| Woimant, F | 2 |
| England, T | 2 |
| Geeganage, C | 2 |
| Christensen, H | 2 |
| De Deyn, PP | 3 |
| Leys, D | 3 |
| O'Neill, D | 3 |
| Ringelstein, EB | 2 |
| Tracy, M | 1 |
| Sare, G | 1 |
| Sprigg, N | 1 |
| Boysen, G | 1 |
| Friis, P | 1 |
| Marttila, R | 1 |
| Olsson, JE | 1 |
| Ringelstein, B | 1 |
| van der Sande, JJ | 1 |
| Lindenstrøm, E | 1 |
| Izzedine, H | 1 |
| Cluzel, P | 1 |
| Deray, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Hypertension
| Article | Year |
|---|---|
[Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
Topics: Aged, 80 and over; Anemia, Hypochromic; Anticoagulants; Bundle-Branch Block; Diabetes Complications; | 2014 |
4 trials available for dalteparin and Hypertension
13 other studies available for dalteparin and Hypertension
| Article | Year |
|---|---|
[Calcified subcutaneous nodules in patients with chronic renal failure as a result of injections with nadroparin (Fraxiparine)].
Topics: Aged; Anticoagulants; Arteriosclerosis; Calcinosis; Female; Humans; Hypertension; Injections, Subcut | 1998 |
[Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter].
Topics: Adult; Aged; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Data Interpreta | 2009 |
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype | 2020 |
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Azithromycin; Combined Moda | 2020 |
Potential drug-drug interactions in ICU patients: a retrospective study.
Topics: Aspirin; Diabetes Mellitus; Drug Interactions; Enoxaparin; Hospitalization; Humans; Hypertension; In | 2020 |
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype | 2020 |
A 15-year-old girl with hypertension.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Cerebral Infarction; Enoxaparin; Female; Huma | 2011 |
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em | 2013 |
Necrotic livedo reticularis, multiple cholesterol emboli and ANCA.
Topics: Abdomen; Aged; Buttocks; Diagnosis, Differential; Embolism, Cholesterol; Enoxaparin; Humans; Hyperch | 2003 |
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk].
Topics: Adult; Anticoagulants; Blood Glucose; Blood Pressure; Body Mass Index; Brain; C-Peptide; Cardiovascu | 2004 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†.
Topics: Animals; Anticoagulants; Dalteparin; Female; Fetal Development; Gene Expression Regulation; Heparin; | 2020 |
Renal radiation-induced arterial stenosis.
Topics: Adult; Angioplasty, Balloon; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hodgkin Disease; Hu | 2007 |